Just two months after telegraphing plans to lay off 641 staffers at two of its Massachusetts sites, Takeda is parting ways ...

As the November U.S. elections near, it's clear that drug pricing will remain an important topic for voters and politicians.

The world’s first injectable immune checkpoint inhibitor likely won’t make it to the U.S. anytime soon after the ...

Inovio has changed its chief commercial officer ahead of the planned launch of its first DNA medicine, putting Merck veteran ...

With four contract modifications totaling more than $250 million, the government is leveling up its agreements with long-time ...

Even as the BIOSECURE Act charts an uncertain path through the legislative process, the draft bill has already seriously ...

After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved ...

Which companies do Americans associate most with weight loss medication? If you answered Eli Lilly or Novo Nordisk, think ...

Under federal law, former FDA employees are prohibited from engaging in certain lobbying activities—but an investigation ...

In an unconventional move, Novartis recently said it will propose Giovanni Caforio, M.D., who recently stepped down as ...

Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad ...

As Korean CDMO giant Samsung Biologics continues to ink production pacts around the globe, the company has added another ...